{"nctId":"NCT00142298","briefTitle":"Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies","startDateStruct":{"date":"2005-03"},"conditions":["Chronic Hepatitis B"],"count":1869,"armGroups":[{"label":"telbivudine","type":"EXPERIMENTAL","interventionNames":["Drug: Telbivudine (LdT)"]}],"interventions":[{"name":"Telbivudine (LdT)","otherNames":["Sebivo®/Tyzeka®","LdT600"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient completed a previous qualifying Idenix-Sponsored trial with telbivudine\n* Patient was not discontinued from previous Idenix-Sponsored study\n\nOther protocol-defined inclusion criteria may apply\n\nExclusion Criteria:\n\n* Patient is pregnant or breastfeeding\n* Patient is co-infected with hepatitis C, hepatitis D or HIV\n\nOther protocol-defined exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"16 Years","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"To Longitudinally Assess the Longer-term Antiviral Efficacy Achieved With Telbivudine Treatment","description":null,"classes":[]},{"type":"SECONDARY","title":"To Longitudinally Assess the Clinical Efficacy of Longer-term Treatment With Telbivudine","description":null,"classes":[]},{"type":"SECONDARY","title":"To Longitudinally Assess the Durability of HBeAg Responses Achieved With Telbivudine Treatment and Other Previous Treatments in Patients","description":null,"classes":[]},{"type":"SECONDARY","title":"To Determine the Longitudinal Frequency of Virologic Breakthrough and Characterize the Associated Mutations in the HBV Polymerase Gene in HBV DNA Amplified From Sera of Patients With Virologic Breakthrough","description":null,"classes":[]},{"type":"PRIMARY","title":"Percentage of Participants Who Maintained Therapeutic Response [Group A: LdT Pool 2302/015]","description":"The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA \\< 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (\\>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"86.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Maintained Therapeutic Response [Group A: LAM Pool 2302/015]","description":"The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA \\< 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (\\>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Who Maintained Therapeutic Response [Group A: Feeder Studies 2401/2402/010]","description":"The maintained therapeutic response is defined as hepatitis B virus (HBV) DNA \\< 5 log10 copies/mL and either hepatitis Be antigen (HBeAg) loss or alanine aminotransferase (ALT) normalized. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is defined as ALT within normal limits for a patient with an elevated ALT level (\\>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.7","spread":null},{"groupId":"OG001","value":"35.4","spread":null},{"groupId":"OG002","value":"69.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.8","spread":null},{"groupId":"OG001","value":"46.7","spread":null},{"groupId":"OG002","value":"76.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"54.1","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":null},{"groupId":"OG001","value":"60.0","spread":null},{"groupId":"OG002","value":"NA","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Maintained Clinical Response [Group B: LdT 2301]","description":"Maintained clinical response is defined as achievement of serum HBV DNA \\< 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient's baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"75.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Maintained Clinical Response [Group B: LAM 2301]","description":"Maintained clinical response is defined as achievement of serum HBV DNA \\< 4 log10 copies/mL, normal serum ALT level and improvement or stabilization in Child-Turcotte-Pugh (CTP) score. Total CTP score ranges from 5 to 15; higher scores indicate liver impairment. Improvement is defined as a 2-point or greater reduction in CTP score, and stabilization is defined as a less than 2-point change in CTP score, compared to the patient's baseline value. Analysis was done on the overall per protocol (PP) population and separately for the HBeAg-positive and HBeAg-negative subpopulation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"72.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Sustained Therapeutic Response [Group C: LdT Pool and LAM Pool (2302/015)]","description":"The primary efficacy endpoint for Group C patients was the percentage of patients with sustained therapeutic response (defined as HBV DNA \\< 5 log10 copies/mL and either HBeAg loss or ALT normalized) at Weeks 52 and 104 of off-treatment follow-up. HBeAg loss is loss of detectable serum HBeAg in a patient who was HBeAg-positive at feeder baseline. ALT normalized is ALT within normal limits for a patient with an elevated ALT level (\\>1.0 × ULN) at either the feeder baseline or feeder screening visit. All efficacy data were analyzed separately for HBeAg-positive and HBeAg-negative patients.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.8","spread":null},{"groupId":"OG001","value":"73.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.1","spread":null},{"groupId":"OG001","value":"62.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"80.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"83.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Sustained Therapeutic Response [Group C: Other Feeder Studies]","description":"The primary efficacy endpoint for Group C (other feeder studies) was the percentage of patients with sustained therapeutic response (defined as HBV DNA \\< 5 log10 copies/mL and either HBeAg loss or ALT normalized) at Weeks 52 and 104 of off-treatment follow-up.\n\nPatients were enrolled for off-treatment follow-up after the treatment discontinuation due to efficacy at their last visit of the feeder studies. Hence, patients did not receive study drug except in case of patients who relapsed and reinitiated treatment. No statistical summary was performed , only patient listing was generated.","classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":45,"n":655},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","NASOPHARYNGITIS","BLOOD CREATINE PHOSPHOKINASE INCREASED","FATIGUE","HEADACHE"]}}}